APA (7th ed.) Citation

K, K., E, K., N, H., M, I., S, A., & Y, S. (2026). NS-229, a novel Janus kinase 1 inhibitor, ameliorates eosinophilic vasculitis in an ovalbumin-induced mouse model by modulating multiple cytokine signaling pathways. The Journal of pharmacology and experimental therapeutics, 393(2), 103806. https://doi.org/10.1016/j.jpet.2026.103806

Chicago Style (17th ed.) Citation

K, Kageyama, Kikuchi E, Hoshino N, Ito M, Akiyama S, and Shiba Y. "NS-229, a Novel Janus Kinase 1 Inhibitor, Ameliorates Eosinophilic Vasculitis in an Ovalbumin-induced Mouse Model by Modulating Multiple Cytokine Signaling Pathways." The Journal of Pharmacology and Experimental Therapeutics 393, no. 2 (2026): 103806. https://doi.org/10.1016/j.jpet.2026.103806.

MLA (9th ed.) Citation

K, Kageyama, et al. "NS-229, a Novel Janus Kinase 1 Inhibitor, Ameliorates Eosinophilic Vasculitis in an Ovalbumin-induced Mouse Model by Modulating Multiple Cytokine Signaling Pathways." The Journal of Pharmacology and Experimental Therapeutics, vol. 393, no. 2, 2026, p. 103806, https://doi.org/10.1016/j.jpet.2026.103806.